anagrelide hydrochloride

FDA Drug Profile — Agrylin

anagrelide hydrochloride is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Agrylin. Available dosage forms: powder, capsule.

Drug Details

Generic Name
anagrelide hydrochloride
Brand Names
Agrylin
Application Number
NDA020333
Sponsor
Zydus Lifesciences Limited
NDC Codes
2
Dosage Forms
POWDER, CAPSULE
Routes
ORAL
Active Ingredients
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE ANHYDROUS

Indications and Usage

1 INDICATIONS AND USAGE AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. AGRYLIN is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )